Geode Capital Management LLC Buys 9,060 Shares of Seres Therapeutics, Inc. (MCRB)
Geode Capital Management LLC increased its stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 5.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 166,325 shares of the biotechnology company’s stock after buying an additional 9,060 shares during the period. Geode Capital Management LLC owned 0.41% of Seres Therapeutics worth $1,874,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of MCRB. State Street Corp increased its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 16,671 shares during the period. Teachers Advisors LLC increased its position in Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock valued at $407,000 after buying an additional 12,462 shares during the period. Bank of Montreal Can increased its position in Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,829 shares during the period. Fox Run Management L.L.C. bought a new position in Seres Therapeutics during the first quarter valued at approximately $136,000. Finally, American Century Companies Inc. bought a new position in Seres Therapeutics during the first quarter valued at approximately $447,000. 74.76% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Seres Therapeutics, Inc. (NASDAQ MCRB) traded up 0.44% during mid-day trading on Wednesday, reaching $13.55. The company had a trading volume of 17,805 shares. The stock has a 50 day moving average of $12.98 and a 200-day moving average of $10.93. Seres Therapeutics, Inc. has a 52 week low of $8.85 and a 52 week high of $15.09. The company’s market capitalization is $548.94 million.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The business had revenue of $3 million during the quarter, compared to analysts’ expectations of $3 million. During the same period in the prior year, the firm posted ($0.70) EPS. Seres Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts expect that Seres Therapeutics, Inc. will post ($2.48) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/30/geode-capital-management-llc-buys-9060-shares-of-seres-therapeutics-inc-mcrb.html.
MCRB has been the topic of several recent research reports. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 4th. Cantor Fitzgerald set a $16.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 4th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 5th. Finally, BidaskClub raised Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $17.00.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.